2002 Fiscal Year Final Research Report Summary
Application of gene therapy on squamous cell carcinoma of the head and neck (SCCHN)
| Project/Area Number |
12671685
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Nihon University |
|---|
Principal Investigator |
ENDO Sohei Sch. Of Med., Dept. of ORL-HNS Assistant Prof., 医学部, 講師 (80246876)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUYAMA Kazuo Sch. Of Med., Dept. of ORL-HNS, 医学部, 助手 (40333108)
KIJIMA Taro Sch. Of Med., Dept. of ORL-HNS, 医学部, 助手 (40256863)
|
|---|
| Project Period (FY) |
2000 – 2002
|
| Keywords | squamous cell carcinoma / head and neck / gene therapy / antisense plasmid vector / transforming growth factor (TGF)-alpha / liposome / cisplatin |
|---|
| Research Abstract |
According to recent meta-analyses, chemotherapy has been proved to be beneficial in improving survival for the patients with squamous cell carcinoma of the head and neck (SCCHN). Cisplatin is the standard chemotherapeutic agent in treating SCCHN patients. Therefore cisplatin resistant is one of the major obstacles in improving survival. At first we established cisplatin-resistant SCCHN cell lines. Then we developed animal model where subcutaneously inoculated SCCHN tumor progresses even with cisplatin administration which were weekly injected intra-peritoneally (IP).
On the other hand, we have also shown that antisense (AS) gene delivery targeting transforming growth factor (TGF)-α was effective in suppressing SCCHN tumor growth in vivo.
This time we succeeded to show the results where simultaneous administration of TGF-α AS plasmid vector injected topically enhanced anti-tumor effects of cisplatin on SCCHN in vivo. This animal design provides a good preclinical model for the treatment of cisplatin-resistant SCCHN.
|
